Source: CureToday articles
Enclosed is the 2025 Quarter 1 – COA Patient Advocacy Network News Bulletin.
Recent Content
- 2025 Quarter 1 – COA Patient Advocacy Network News Bulletin.
- EPA Deregulation Means More Air Pollution and More Cancer Deaths
- FDA Approved NDA for Aficamten to Treat Patients With Obstructive Hypertrophic Cardiomyopathy
- Understanding Unique Treatment Options Across Bladder Cancer Care
- Evaluation of Antibiotic Administration Surrounding Interventional Radiology Procedures
- Brain Cancer Awareness Month Highlights Advances in Radiation Therapy
- Adding Pertuzumab to Trastuzumab and Chemotherapy Reduced Risk of Death by 17% in HER2+ Breast Cancer
- Several Comorbidities Found to Reduce Likelihood of Pneumococcal Vaccination, While Use of Implantable Devices Heightens Odds
- Omalizumab: An All-in-One Allergy Wonder Drug?
- Durvalumab Regimen Improves Disease-Free Survival in High-Risk Non-Muscle-Invasive Bladder Cancer